Tumor biomarker analysis from COLUMBUS part 1: Encorafenib plus binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma

被引：2

作者：

Dummer, R. ^{[1
]}

Pathan, N. ^{[2
]}

Deng, S. ^{[3
]}

Robert, C. ^{[4
,5
]}

Fernandez, A. M. Arance ^{[6
]}

de Groot, J. W. B. ^{[7
]}

Garbe, C. ^{[8
]}

Gogas, H. J. ^{[9
]}

Gutzmer, R. ^{[10
]}

Krajsova, I. ^{[11
]}

Liszkay, G. ^{[12
]}

Loquai, C. ^{[13
]}

Mandala, M. ^{[14
]}

Schadendorf, D. ^{[15
,16
]}

Yamazaki, N. ^{[17
]}

di Pietro, A. ^{[18
]}

Xie, T.

Ascierto, P. A. ^{[19
]}

Flaherty, K. ^{[20
]}

机构：

[1] Univ Spital Zurich, Klin Dermatol, Dermatol Dept, Zurich, Switzerland

[2] Pfizer, Translat & Immuno Oncol, Global Prod Dev, La Jolla, CA USA

[3] Pfizer, Oncol Res Unit, San Diego, CA USA

[4] Gustave Roussy, Dermatol, Villejiuf, France

[5] Paris Saclay Univ, Villejiuf, France

[6] Hosp Clin Prov Barcelona, Med Oncol Dept, Barcelona, Spain

[7] Isala Oncol Ctr, Med Oncol, Zwolle, Netherlands

[8] Univ Hautklin Tuebingen, Dermatol, Tubingen, Germany

[9] Natl & Kapodistrian Univ Athens, Dept Med 1, Athens, Greece

[10] Ruhr Univ Bochum Campus Minden, Johannes Wesling Med Ctr, Dermatol, Minden, Germany

[11] Univ Hosp Prague, Dermato Oncol, Prague, Czech Republic

[12] Natl Inst Oncol Hungary, Oncol Internal Med, Budapest, Hungary

[13] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dermatol, Mainz, Germany

[14] Univ Perugia, Med Oncol, Perugia, Italy

[15] Univ Hosp Essen, West German Canc Ctr, Dermatol, Essen, Germany

[16] German Canc Consortium, Partner Site Essen, Essen, Germany

[17] Natl Canc Ctr, Dermatol Oncol Dept, Tsukiji Campus,Chuo Ku, Tokyo, Japan

[18] Pfizer, Oncol Res & Dev, San Diego, CA USA

[19] IRCCS Fdn Pascale, Ist Nazl Tumori, Canc Immunotherapy & Dev Therapeut, Melanoma, Naples, Italy

[20] MGH Massachusetts Gen Hosp, Hematol Oncol, Boston, MA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.912

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

786O

引用

页码：S902 / S902

页数：1

共 50 条

[21] Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
Long, G. V.
Flaherty, K. T.
Stroyakovskiy, D.
Gogas, H.
Levchenko, E.
de Braud, F.
Larkin, J.
Garbe, C.
Jouary, T.
Hauschild, A.
Chiarion-Sileni, V.
Lebbe, C.
Mandala, M.
Millward, M.
Arance, A.
Bondarenko, I.
Haanen, J. B. A. G.
Hansson, J.
Utikal, J.
Ferraresi, V.
Mohr, P.
Probachai, V.
Schadendorf, D.
Nathan, P.
Robert, C.
Ribas, A.
Davies, M. A.
Lane, S. R.
Legos, J. J.
Mookerjee, B.
Grob, J. -J.
ANNALS OF ONCOLOGY, 2017, 28 (07) : 1631 - 1639
[22] Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma
Dummer, Reinhard
Ascierto, Paolo A.
Gogas, Helen J.
Arance, Ana
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsovÿ, Ivana
Gutzmer, Ralf
Sileni, Vanna Chiarion
Dutriaux, Caroline
de Groot, Jan Willem B.
Yamazaki, Naoya
Loquai, Carmen
de Parseval, Laure A.
Pickard, Michael
Sandor, Victor
Berking, Carola
Robert, Caroline
Flaherty, Keith T.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 12 - 13
[23] Encorafenib (enco) plus binimetinib (bini) plus pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).
Schadendorf, Dirk
Dummer, Reinhard
Robert, Caroline
Ribas, Antoni
Sullivan, Ryan J.
Panella, Timothy J.
McKean, Meredith
Santos, Edgardo S.
Clancy, Jill S.
Thakur, Mahgull Nazar
Polli, Anna
Di Pietro, Alessandra
Ascierto, Paolo Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] Five- year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma
Robert, Caroline
Flaherty, Keith
Nathan, Paul
Hersey, Peter
Garbe, Claus
Milhem, Mohammed
Demidov, Lev
Mohr, Peter
Hassel, Jessica C.
Rutkowski, Piotr
Dummer, Reinhard
Utikal, Jochen
Kiecker, Felix
Larkin, James
D'Amelio, Anthony, Jr.
Mookerjee, Bijoyesh
Schadendorf, Dirk
EUROPEAN JOURNAL OF CANCER, 2019, 109 : 61 - 69
[25] BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy
Sloot, Sarah
Zager, Jonathan S.
Kudchadkar, Ragini R.
Messina, Jane L.
Benedict, Jacob J.
Gonzalez, Ricardo J.
DeConti, Ronald
Turner, Leslie M.
McCardle, Timothy
Smalley, Keiran S. M.
Weber, Jeffrey S.
Sondak, Vernon K.
Gibney, Geoffrey T.
MELANOMA RESEARCH, 2016, 26 (01) : 83 - 87
[26] COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma
Dummer, Reinhard
Flaherty, Keith T.
Robert, Caroline
Arance, Ana
de Groot, Jan Willem B.
Garbe, Claus
Gogas, Helen J.
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Schadendorf, Dirk
Yamazaki, Naoya
di Pietro, Alessandra
Cantey-Kiser, Jean
Edwards, Michelle
Ascierto, Paolo A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36) : 4178 - +
[27] Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma
Haydon, Andrew
Dummer, Reinhard
Flaherty, Keith
Robert, Caroline
Arance, Ana M.
de Groot, Jan Willem
Garbe, Clause
Gogas, Helen
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Schadendorf, Dirk
Yamazaki, Naoya
Zohren, Fabien
Atkinson, Victoria
Millward, Michael
Hill, Andrew
Edwards, Michelle L.
Ascierto, Paolo A.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 123 - 124
[28] Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma
Dummer, R.
Ascierto, P. A.
Gogas, H.
Arance, A.
Mandala, M.
Liszkay, G.
Garbe, C.
Schadendorf, D.
Krajsova, I.
Gutzmer, R.
Sileni, V. Chiarion
Dutriaux, C.
de Groot, J. W. B.
Yamazaki, N.
Loquai, C.
de Parseval, L. A.
Pickard, M.
Sandor, V.
Robert, C.
Flaherty, K. T.
ANNALS OF ONCOLOGY, 2017, 28
[29] Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
Riely, G. J.
Ahn, M-J.
Clarke, J.
Dagogo-Jack, I.
Felip, E.
Gelsomino, F.
Goldman, J. W.
Hussein, M.
Johnson, M. L.
Morgensztern, D.
Nadal, E.
Offin, M. D.
Provencio Pulla, M.
Ramalingam, S. S.
Smit, E. F.
Tsao, A. S.
Alcasid, A.
Usari, T.
Wilner, K.
Johnson, B.
ANNALS OF ONCOLOGY, 2024, 35 : 1246 - 1247
[30] Circulating tumor DNA as biomarker for disease activity and response to treatment in BRAF V600E mutant malignant melanoma
von Bubnoff, D.
Follo, M.
Graf, E.
Pfeifer, D.
Duyster, J.
Meiss, F.
von Bubnoff, N.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 100 - 101

← 1 2 3 4 5 →